FASLODEX
Main information
- Trade name:
- FASLODEX 1 U. INJ
- Active ingredient:
- FULVESTRANT
- Available from:
- Astrazeneca
- Dosage:
- 250MG (IN 5ML. SOL. ETHANOL 96%)
- Pharmaceutical form:
- INJ
- Composition:
- 1 U.
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
18-10-2016
FASLODEX (fulvestrant) - Risk of Unnecessary Therapy Modification due to Falsely Elevated Estradiol Levels
MedEffect Canada
29-8-2018
Fulvestrant Mylan (Mylan S.A.S.)
Fulvestrant Mylan (Active substance: fulvestrant) - Centralised - 2-Monthly update - Commission Decision (2018)5774 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/004649/IB/0001
Europe -DG Health and Food Safety
15-5-2018
Faslodex (AstraZeneca AB)
Faslodex (Active substance: Fulvestrant) - Corrigendum - Commission Decision (2018)1898 of Tue, 15 May 2018
Europe -DG Health and Food Safety